Abstract 18235: Plasma miRNAs Are Related to Atrial Fibrillation Recurrence After Catheter Ablation: Longitudinal Findings From the miRhythm Study
Introduction: Catheter ablation for atrial fibrillation (AF) has emerged as a mainstay of therapy for reducing arrhythmia burden for symptomatic AF patients. Nevertheless, AF recurrence after ablation is common and little is known about the mechanisms that drive recurrence. Genetic and/or epigenetic changes are thought to contribute to AF recurrence. We hypothesized that circulating miRNAs relate to AF recurrence in a cohort of patients undergoing ablation.
Methods: We quantified plasma expression of 86 miRNAs by qRT-PCR in 112 patients with symptomatic AF who underwent catheter ablation. Participants were screened with ECG and Holter monitors at 1, 6, and 12 months plus for symptomatic recurrences to ascertain for AF recurrence. miRNA expression at baseline was normalized to a global mean and then levels of miRNAs were compared between participants with and without clinically significant (>3 months) AF recurrence.
Results: The average age of the study population was 60.4 ±11.0 years (69.6% women), with a 40.4%. rate of clinically significant AF recurrence. Four miRNAs were associated with AF recurrence after global mean normalization and adjustment for CHA2DS2-VASc score in our regression models. ΔCT levels of miRs-125a (-3.57 vs -2.12, p<0.001), 148b (-1.79 vs -0.83, p<0.01), miR-199b (0.46 vs 3.19, p<0.01) and 30c (-1.31 vs -0.45, p<0.01) were lower among patients with AF recurrence suggesting upregulation of these miRs.
Conclusions: We observed strong differences between 4 miRNAs implicated in cardiac gene regulation with AF recurrence over 12 months in symptomatic AF patients undergoing catheter ablation. miRs 125a, 148b and 30c were found to be associated with AF in the original miRhythm study as well. Our findings warrant further investigation but implicate miRNAs as key contributors to altered cardiac gene regulation after ablation and suggest that miRNAs may be useful predictors of arrhythmia recurrence.
Author Disclosures: A. Vaze: None. K. Tanriverdi: None. M. Spring: None. T. Fitzgibbons: None. K. Donahue: None. J.F. Keaney: None. C. Ennis: None. C. Browning: None. L. Rosenthal: None. K. Floyd: None. P.T. Ellinor: None. S. Lubitz: None. J. Freedman: None. D. McManus: None.
- © 2016 by American Heart Association, Inc.